Macrolide-Resistant and Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia in Children Treated Using Early Corticosteroids
Autor: | Ki Cheol Park, Eun-Ae Yang, Kyung-Yil Lee, Hye Young Han |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Mycoplasma pneumoniae corticosteroid medicine.drug_class lcsh:Medicine medicine.disease_cause Gastroenterology Serology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 23S ribosomal RNA Internal medicine Lactate dehydrogenase medicine pneumonia 030212 general & internal medicine Mycoplasma pneumoniae pneumonia 0303 health sciences child 030306 microbiology business.industry Macrolide resistant lcsh:R macrolide General Medicine medicine.disease Pneumonia chemistry Corticosteroid business |
Zdroj: | Journal of Clinical Medicine Volume 10 Issue 6 Journal of Clinical Medicine, Vol 10, Iss 1309, p 1309 (2021) |
ISSN: | 2077-0383 |
DOI: | 10.3390/jcm10061309 |
Popis: | We have found that early corticosteroid therapy was effective for reducing morbidity during five Korea-wide epidemics. We evaluated the clinical and laboratory parameters of 56 children who received early corticosteroid treatment for pneumonia that was caused by macrolide-resistant Mycoplasma pneumoniae (M. pneumoniae) or macrolide-sensitive M. pneumoniae between July 2019 and February 2020. All subjects had dual positive results from a PCR assay and serological test, and received corticosteroids within 24–36 h after admission. Point mutation of residues 2063, 2064, and 2067 was identified in domain V of 23S rRNA. The mean age was 6.8 years and the male:female ratio was 1.2:1 (31:25 patients). Most of the subjects had macrolide-resistant M. pneumoniae (73%), and all mutated strains had the A2063G transition. No significant differences in clinical and laboratory parameters were observed between macrolide-resistant and macrolide-sensitive M. pneumoniae groups that were treated with early dose-adjusted corticosteroids. Higher-dose steroid treatment may be needed for patients who have fever that persists for > 48 h or increased biomarkers such as lactate dehydrogenase concentration at follow-up despite a usual dose of steroid therapy. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |